

RECEIVED
CENTRAL FAX CENTER

JUN 29 2006

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	PCT/EP2003/014562
	Filing Date	18 December 2003
	First Named Inventor	Gary DUBIN
	Title	HPV-16 AND -18 L1 VLP VACCINE
	Att Unit	
	Examiner Name	
	Attorney Docket Number	B45331

I hereby appoint:	
<input checked="" type="checkbox"/> Practitioners associated with the Customer Numbers.	20462
Or	
<input type="checkbox"/> Practitioner(s) named below:	
Name	Registration Number
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.	
Please recognize or change the correspondence address for the above-identified application to:	
<input type="checkbox"/> The address associated with the above-mentioned Customer Number:	
Or	
<input checked="" type="checkbox"/> The address associated with Customer Number 20462	
Or	
<input type="checkbox"/> Firm or Individual Name:	
Address:	
Address:	
City:	State: Zip:
Country:	
Telephone:	Fax:
I am the:	
<input type="checkbox"/> Applicant/Inventor:	
<input checked="" type="checkbox"/> Assignee or record of the entire interest. See 37 CFR 3.71.	
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)	
SIGNATURE of Applicant or Assignee of Record	
Signature: <i>Marcus Jonathan William Dalton</i>	Date: 05 AUG 2005
Name: Marcus Jonathan William DALTON	Telephone: +44 20 8047 4401
Title and Company: Attorney and Authorised Official, GlaxoSmithKline Biologicals sa	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.	
<input type="checkbox"/> *Total of: forms are submitted.	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

RECEIVED
CENTRAL FAX CENTER


JUN 29 2006

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: GlaxoSmithKline Biologicals sa	
International Application No./Patent No.: <u>PCT/EP2003/014562</u>	Filed/Issue Date: <u>18 December 2003</u>
Entitled: HPV-16 AND -18 L1 VLP VACCINE	
GlaxoSmithKline Biologicals sa, a corporation, states that it is:	
1. <input checked="" type="checkbox"/> the assignee of the entire right, title, and interest, or	
2. <input type="checkbox"/> an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is _____ % in the patent application/patent identified above by virtue of either,	
A. <input type="checkbox"/> An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which copy thereof is attached.	
OR	
B. <input type="checkbox"/> A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:	
1. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
2. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
3. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
<input type="checkbox"/> Additional documents in the chain of title are listed on a supplemental sheet.	
<input checked="" type="checkbox"/> Copies of assignments or other documents in the chain of title are attached.	
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
 Signature	<u>05 AUG 2005</u> Date
<u>Marcus Jonathan William DALTON</u> Printed or Typed Name	<u>+44 20 8047 4401</u> Telephone Number
<u>Attorney and Authorised Official</u> Title	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

Docket No.: B45331

ASSIGNMENT

WHEREAS I/We, Moncef Mohammed SLAOUI of King of Prussia, Pennsylvania, United States of America (formerly of Rixensart, Belgium) and Martine Anne Cecile WETTENDORFF of Rixensart, Belgium have made an invention entitled:

HPV-16 AND -18 L1 VLP VACCINE

for which on July 14, 2005, August 22, 2005 I/we executed an application for Letters Patent of the United States of America;

NOW, THEREFORE, in return for valuable consideration paid to me/us by GlaxoSmithKline Biologicals sa of rue de l'Institut 89, B-1330 Rixensart, Belgium (hereinafter "ASSIGNEE"), the receipt of which is hereby acknowledged and intending to be legally bound I/we do hereby assign unto the said ASSIGNEE, its successors and assigns, the entire right, title and interest in and to the said invention, said executed application, any division, continuation and continuation-in-part of said application and reissue applications, and all Letters Patents of the United States of America to be obtained therefor;

I/we hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

In addition I/we agree to provide ASSIGNEE upon its request with all pertinent facts and documents relating to said invention, and said Letters Patent as may be known and accessible to me/us, and to testify as to the same in any interference or litigation related thereto, and to execute further instruments (including divisional, continuation, continuation-in-part or reissue applications, affidavits or other instruments) required to apply for, obtain, maintain and enforce said application and said Letters Patent which may be necessary; this agreement to be binding upon my/our heirs, executors and administrators.


Inventor 1
Moncef Mohammed SLAOUI

Date: July 14, 2005


Inventor 2
Martine Anne Cecile WETTENDORFF

Date: August 22, 2005

BEST AVAILABLE COPY

B45331
Docket Number**Assignment**

WHEREAS, I/we Gary DUBIN and Bruce INNIS, all citizens of the United States of America and residing at King of Prussia, Pennsylvania, has/have invented or discovered certain improvements in HPV-16 AND -18 L1 VLP VACCINE hereinafter referred to as said invention and improvements for which a priority application 60/435035 was filed on 20 December 2002 in the United States Patent and Trademark Office and priority application 60/496653 was filed on 20 August 2003 in the United States Patent and Trademark Office and for which a PCT international application is now being filed designating the United States of America and naming assignor as inventor, and in the United States only applicant/inventor. I/We hereby authorize and request that the filing date and application number of said PCT application, when known be inserted in parentheses below.

(PCT/EP2003/014562 filed 18 December 2003)

WHEREAS, GLAXOSMITHKLINE BIOLOGICALS SA, a company incorporated in Belgium, whose registered office is at Rue de l'Institut 89, B-1330 Rixensart, Belgium, is desirous of acquiring the whole right, title and interest in and to said invention and improvements, and in and to any applications for said invention and improvements and any Letters Patent to be obtained therefor, in all countries, including the United States, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, Gary DUBIN and Bruce INNIS for good and valuable consideration unto me/us moving the receipt whereof is hereby acknowledged, have sold, assigned and transferred, and by these presents do sell, assign and transfer my/our whole right, title and interest in and to said invention and improvements to said GLAXOSMITHKLINE BIOLOGICALS SA, throughout the United States of America, its territories and possessions, and in and to said application and any extensions, reissues, continuations, continuations-in-part, and any divisions thereof, and in and to any and all Letters Patent of the United States of America;

AND, my/our whole right, title and interest in and to said invention and improvements to GLAXOSMITHKLINE BIOLOGICALS SA, in all other countries throughout the world, and in and to any applications in said other countries, and continuations-in-part, patents of addition, revalidation patents, patents of importation, registrations, and any renewals, extensions and divisions thereof, and in and to any and all

B45331
Docket Number


Letters Patent of said all other countries which may be granted on said invention and improvements including any priority rights under the International Convention.

AND, I/we do hereby authorize and request the issue of any Letters Patent in the respective areas referred to, to said **GLAXOSMITHKLINE BIOLOGICALS SA**, as assignees of my/our whole right, title and interest in and to the same for the sole use and behoof of the said assignees, their successors and assigns as their interests appear herein;

AND, I/we warrant that I/we have not knowingly conveyed to others any right in said invention, improvements, applications or patents or any license to use the same or to make, use or sell anything embodying or utilizing said invention and improvements and that I/we have good right to assign the same to **GLAXOSMITHKLINE BIOLOGICALS SA**;

AND, I/we the undersigned **Gary DUBIN** and **Bruce INNIS** for the consideration aforesaid, do hereby agree that I/we or my/our executors or legal representatives, will provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, application papers, affidavits, assignments and other documents which may be necessary or desirable to more effectually secure to and vest in said **GLAXOSMITHKLINE BIOLOGICALS SA**, their successors and assigns, the whole right, title and interest in and to the said invention and improvements, applications, Letters Patent, rights, title and interest hereby sold, assigned and conveyed, or intended so to be. *This assignment should be deemed effective as of 20 December 2002.*

IN WITNESS WHEREOF, I/we have hereunto set my/our hand(s) and affixed my/our seal(s) on the date(s) indicated below.



Inventor: **Gary DUBIN** June 24, 2005
Date

IN WITNESS WHEREOF, I/we have hereunto set my/our hand(s) and affixed my/our seal(s) on the date(s) indicated below.



Inventor: **Bruce INNIS** June 24, 2005
Date